Akhil Akula joined New Rhein as a Vice President in 2022. Akhil shares responsibilities including identification and screening of new opportunities, due diligence, negotiation of deal structure,
and portfolio company management.
Prior to joining New Rhein, Akhil worked at Pfizer on the corporate development team. While at Pfizer, Akhil executed several large M&A and licensing transactions and renegotiated existing partnerships. Akhil was also a founding member of the Pfizer Breakthrough Growth Initiatives (“PBGI”), a $500 million vehicle used to invest in early stage private and public biotech companies. In addition to executing and negotiating PBGI equity investments, he also managed the PBGI portfolio.
Prior to Pfizer, Akhil was an associate at Healthcare Royalty Partners (“HCR”), where he worked on the investment team and supported various activities, including financial analysis, transaction structuring, due diligence and portfolio management. Before joining HCR, Akhil worked in healthcare investment banking at MTS Health Partners and Ziegler. During his career, Akhil has helped execute over $10 billion of transactions.
Akhil graduated from the University of Richmond with a B.S. in Business Administration and concentration in Finance. Akhil also completed the pre-medicine curriculum. In his free time, he enjoys traveling, volunteering with Korean K9 rescue shelter, trying new restaurants, racing cars and is a member of the Classic Car Club of Manhattan.